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Hepatitis C virus infection is a major health problem worldwide
and no vaccine has yet been developed against this virus. In addi-
tion, currently approved pharmacotherapies achieve suboptimal
cure rates and have side effects that result in non-compliance
and premature treatment discontinuation. Signiﬁcant research
has been devoted to developing direct-acting antiviral agents that
inhibit key viral functions. In particular, several novel drug candi-
dates that inhibit the viral non-structural protein 5A (NS5A) have
been demonstrated to possess high potency, pan-genotypic activ-
ity, and a high barrier to resistance. Clinical trials using combina-
tion therapies containing NS5A inhibitors have reported results
that promise high cure rates and raise the possibility of develop-
ing interferon-free, all-oral regimens.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Recent estimates indicate that there are more than 120–130 mil-
lion chronic hepatitis C virus (HCV) carriers worldwide [1], who
are at risk of developing cirrhosis and/or hepatocellular carci-
noma (primary liver cancer). As many as 4 million persons are
thought to be chronically infected in the US [2], 5–10 million in
Europe [2], 12 million in India [2], and 1.2 million in Japan
(2004 ﬁgure) [3]. Most of these individuals are not aware of their
infection. The incidence of acute infection in the US has declined
from 7.4/100,000 in 1982 to 0.7/100,000 in recent years, primar-
ily due to screening of blood in transfusion centres and improved
safety of intravenous drug use [4]. It is estimated that approxi-
mately 150,000 new cases occur annually in the United States
and in Western Europe, and about 350,000 in Japan. Only 25%Journal of Hepatology 20
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cases progress to chronic infection and liver disease, and up to
20% of chronic infections progress to cirrhosis [2]. Every year,
4–5% of cirrhotic patients develop hepatocellular carcinoma [5].
Despite the decrease in HCV incidence, the number of patients
with chronic HCV-related complications is increasing in those
aging patients who have been infected for many years, and
chronic hepatitis C infection will continue to be a signiﬁcant
cause of premature mortality, causing at least 200,000–300,000
deaths per year worldwide [4].
A number of direct-acting antiviral agents (DAAs) are under
development for the treatment of chronic HCV infection. These
agents block viral production by directly inhibiting one of several
steps of the HCV lifecycle. As shown in Fig. 1, the genomic orga-
nization of HCV has been elucidated, and several viral proteins
involved in the HCV lifecycle, such as the non-structural (NS) 3/
4A serine protease, the NS5B RNA-dependent RNA polymerase
(RdRp), and the NS5A protein, have been targeted for drug devel-
opment [4]. Two NS3/4A protease inhibitors, telaprevir and boce-
previr, which inhibit post-translational processing of the HCV
polyprotein into individual non-structural proteins, have been
approved by the US Food and Drug Administration, the European
Medicines Agency, and several other regulatory agencies for the
treatment of chronic HCV genotype 1 infection in combination
with pegylated interferon (IFN)-a and ribavirin [6,7].HCV structure and lifecycle, and physiological role of the NS5A
protein
HCV is an enveloped virus with a single-stranded positive RNA
genome of approximately 9.6 kb. At the ﬂanking ends of the gen-
ome are 2 highly conserved untranslated regions (UTRs). The 50
UTR is highly structured and contains the internal ribosome entry
site (IRES), which is important for the initiation of the cap-inde-
pendent translation of the polyprotein [8]. The 30 UTR consists of
a short genotype-speciﬁc variable region, a tract consisting solely
of pyrimidine residues (predominantly uridine) and a conserved
98-nucleotide sequence, known as X region, containing 3 stem-
loops [9,10]. The HCV open reading frame is situated between
the two UTRs.
After entering the bloodstream, HCV binds to a receptor com-
plex at the surface of its target cells, the hepatocytes. The enve-
lope glycoproteins E1 and E2 are essential for target cell
recognition, binding, and internalization [11]. The bound virus13 vol. 59 j 375–382
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Fig. 1. Structural organization of HCV RNA and viral proteins. NS, non-
structural; UTR, untranslated region.
Reviewthen undergoes clathrin-mediated endocytosis [12]. Acidiﬁcation
of the endocytosis vesicle frees the genomic RNA from the nucle-
ocapsid for release into the cytoplasm. Along with host RNA mol-
ecules, the viral RNA migrates to the endoplasmic reticulum (ER).
Binding of the 40S ribosomal subunit to the HCV IRES produces a
stable pre-initiation complex that begins translation of the viral
open reading frame to generate an approximately 3000 amino
acid polyprotein. Following translation, the polyprotein is cleaved
by both cellular and viral proteases to produce at least 10 viral
proteins, including structural proteins (core, E1 and E2) and
non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and
NS5B) [13,14].
Viral replication (i.e., the synthesis of new positive RNA gen-
omes that may also serve as messenger RNAs for viral protein
synthesis) is catalyzed by the viral RdRp, or NS5B protein. A neg-
ative-strand intermediate of replication is initially produced,
which then serves as a template for the synthesis of numerous
positive strands. The NS5A viral protein has been shown to play
an important role in the regulation of replication. In addition,
host cell proteins, such as cyclophilin A, act as necessary co-fac-
tors of HCV replication through their interactions with both
NS5A and the RdRp in the replication complex [15,16].
The non-structural NS5A protein bears pleiotropic functions,
including roles in viral replication and assembly, and complex
interactions with cellular functions. The latter include inhibition
of apoptosis and promotion of tumorigenesis, both of which may
play a role in the triggering of the hepatocarcinogenic process
[17–20]. The protein is comprised of approximately 447 amino
acids and localizes to ER-derived membranes. It basally exists
in phosphorylated (p56) and hyperphosphorylated (p58) forms
that are implicated in different functions [21–23]. Its cytoplasmic
moiety contains 3 domains, of which Domain I is the most con-
served [24]. The mechanism by which NS5A regulates replication
regardless of the HCV genotype is still unclear [25]. Considerable
information has been gathered on its molecular interactions and
role in the viral lifecycle. NS5A and the RdRp directly interact,
both in vivo and in vitro [26]. In vitro, this interaction stimulates
RdRp-catalyzed synthesis of the negative RNA strand [27]. It was
shown that all 3 domains of NS5A bind to RNA [9]. The interac-
tions of Domain I with the polypyrimidine tract of 30 UTR suggest
it may affect the efﬁciency of RNA replication by the RdRp; how-
ever, these results also suggested the binding of RdRp and NS5A
to RNA are mutually exclusive. In addition, Domain II of NS5A376 Journal of Hepatology 201interacts with cyclophilin A, a host cell protein required for
replication, and this interaction is vital for RNA binding [28].
NS5A also plays a role in viral packaging and assembly. Domain
III appears to be essential for this function [29,30]. This may be
due, at least in part, to NS5A recruiting apolipoprotein E, a com-
ponent of the HCV production process [29,31]. Indeed, inhibiting
apolipoprotein E expression results in marked reduction of infec-
tious particle production without affecting viral entry and repli-
cation [31].NS5A inhibitor mechanism of action
Several viral proteins have generated interest as potential targets
for speciﬁc inhibitory drugs. In addition to the two NS3/4A prote-
ase inhibitors already approved for clinical use, numerous other
protease inhibitors are being developed as well as inhibitors of
viral replication, including nucleoside/nucleotide analogue inhib-
itors of HCV RdRp, non-nucleoside inhibitors of RdRp, cyclophilin
inhibitors, and NS5A inhibitors.
Because of its critical involvement in viral replication and
assembly [32], NS5A has been identiﬁed as a target for viral inhi-
bition, leading to development of therapeutic agents. In HCV rep-
licon-containing cells, inhibition of NS5A, but not other HCV
proteins, resulted in redistribution of NS5A from the ER to lipid
droplets. NS5A-targeting agents did not cause similar alterations
in the localization of other HCV-encoded proteins, and the trans-
fer of NS5A to lipid droplets coincided with the onset of inhibition
of replication [33]. Inhibition of NS5A at picomolar concentra-
tions has been associated with signiﬁcant reductions in HCV
RNA levels in cell culture-based models, which makes these
agents among the most potent antiviral molecules yet developed
[34–36]. NS5A inhibitors have pan-genotypic activity, i.e., they
suppress replication of all HCV genotypes, but their antiviral
effectiveness against genotypes other than 1 may vary from one
molecule to another [35]. Use of multiple DAAs including an
NS5A inhibitor in replicon systems in cell culture has resulted
in additive/synergistic inhibition of viral production and an
increased barrier to resistance [37].
The exact mechanism of antiviral action of NS5A inhibitors is
unknown. Available evidence suggests that they have multiple
effects, which contribute to their potency [32]. One putativemech-
anism is the inhibition of hyperphosphorylation. Phosphorylation
of NS5A seems required for viral production [38], but the relative
roles of the phosphorylated and hyperphosphorylated forms are
unclear, and conﬂicting results have been reported suggesting that
reduced hyperphosphorylationmay either enhance or reduce rep-
lication [21,39]. It is thought that a tightly regulated control of
phosphorylation vs. hyperphosphorylation is required for efﬁcient
viral function. It was also shown that NS5A acts in two different
pathways in RNA replication, and one of them likely requires
hyperphosphorylation [23]. However, othermechanismsmay also
play a role. For instance,NS5A inhibitors alter the subcellular local-
ization of NS5A, which may cause faulty viral assembly [33,40].Resistance to NS5A inhibitors
HCV displays a large degree of genomic variability, resulting in its
quasispecies distribution [41]. Variants that confer resistance to
NS5A inhibitors pre-exist within HCV quasispecies populations
in the absence of any previous exposure to these drugs.3 vol. 59 j 375–382
Table 1. Resistance proﬁle of daclatasvir in the in vitro genotype 1a and 1b replicon systems. Adapted from Fridell et al. [43].
Replicon Substitution(s) Replication level (%) 
Average ± SD
EC50 (ng/ml)
Average ± SD
Fold resistance
Genotype 1a WT 100 0.0044 ± 0.0028 1
M28A 27 ± 25 20.2 ± 13.3 4591
M28T 31 ± 23 3.0 ± 0.3 682
M28V 16 ± 11 0.0055 ± 0.0019 1.3
Q30E 130 ± 56 110.9 ± 66.0 25,205
Q30H 75 ± 31 6.5 ± 1.4 1477
Q30R 41 ± 16 5.4 ± 1.8 1227
Q30K 19 ± 9 108 ± 52 24,545
L31M 55 ± 15 1.5 ± 0.5 341
L31V 117 ± 29 14.9 ± 4.4 3386
H58D 92 ± 9 2.2 ± 0.3 500
H58P 266 ± 261 0.0053 ± 0.0006 1.2
Y93C 11 ± 7 8.2 ± 3.0 1864
Y93H 18 ± 11 23.9 ± 7.0 5432
Y93N 13 ± 8 208.9 ± 47.9 47,477
M28V + Q30R 147 ± 55 1.4 ± 0.013 350
Q30H + Y93H 20 ± 6 409.8 ± 153.6 93,136
Q30R + H58D 60 ± 12 1867 ± 46 424,318
Genotype 1b WT 100 0.0019 ± 0.0007 1
L31M 99 ± 23 0.0062 ± 0.0014 3
L31V 158 ± 54 0.053 ± 0.015 28
Q54H 83 ± 18 0.0024 ± 0.0003 1
Q54N 83 ± 29 0.0027 ± 0.0006 1
Y93H 27 ± 16 0.046 ± 0.018 24
L31M + Y93H 70 ± 68 13.5 ± 12.2 7105
L31V + Y93H 50 ± 38 28.1 ± 24.7 14,789
Q54H + Y93H 22 ± 7 0.018 ± 0.005 9
L31V + Q54H + Y93H 189 ± 25 36.1 ± 7.7 19,000
JOURNAL OF HEPATOLOGYThese variants generally replicate at low levels and are thus
undetectable by currently available techniques. However, they
can be selected if an NS5A inhibitor is administered and may
be grown to high levels. Clinically signiﬁcant resistance is usually
associated with an escape pattern whereby viral replication
returns to pretreatment levels and the dominant virus harbours
amino acid substitutions that confer high levels of drug resistance
without impairing ﬁtness of the virus. Very high levels of the drug
may be required to suppress highly resistant viruses, which may
not be achievable without compromising safety [42].
At present, only genotype 1, the most prevalent HCV geno-
type, has been studied in detail for resistant variants. Table 1,
adapted from Fridell et al. [43], describes the resistance proﬁle
of the NS5A inhibitor daclatasvir in genotype 1a and 1b replicons.
The barrier to resistance is lower for genotype 1a than for geno-
type 1b. Substitutions at positions L31 and Y93 have the greatest
ability to confer resistance to daclatasvir, and double mutations
may increase the EC50 to a far greater extent (Table 1). These
substitutions also confer resistance to other ﬁrst-generation
NS5A inhibitors. In addition, studies with daclatasvir have shown
that double and triple inhibitor combinations in replicon systems
can generate resistance pathways that differ from those observed
during NS5A inhibitor monotherapy [37]. Agents without cross-
resistance with NS5A inhibitors should thus be used in combina-
tion with this class of drugs.Journal of Hepatology 201NS5A inhibitors undergoing clinical trials
Although no NS5A inhibitor has yet been approved for therapeu-
tic use, these agents are viewed with optimism due to their
favourable characteristics, including the requirement for low dos-
ing to inhibit HCV replication; pan-genotypic activity; once-daily
dosing; resistance proﬁles that do not overlap with those of other
DAAs in development; and successful suppression of HCV replica-
tion with an acceptable safety proﬁle in early clinical trials [34].Daclatasvir (BMS790052)
Daclatasvir is an oral, once-daily, highly selective NS5A inhibitor
with broad coverage of HCV genotypes in vitro developed by Bris-
tol-Myers Squibb. Daclatasvir currently is in Phase III clinical tri-
als. Its inhibitory target maps to Domain I, and it has been shown
to block hyperphosphorylation of NS5A [23], as well as alter the
subcellular localization of the viral protein [33,40]. Daclatasvir
has an EC50 of 50 pM against genotype 1a, 9 pM against genotype
1b, and 28 pM against genotype 2a [35]. Daclatasvir has been
tested in Phase II clinical trials in combination with pegylated
IFN-a and ribavirin; in quadruple combination with asunaprevir,
an NS3/4A protease inhibitor, and pegylated IFN-a/ribavirin; and
with asunaprevir, the nucleotide analogue sofosbuvir and the3 vol. 59 j 375–382 377
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non-nucleoside inhibitor of HCV RdRp BMS-791325 in IFN-free
regimens.
In a randomized, parallel-group, double-blind, placebo-con-
trolled, dose-ﬁnding Phase IIa trial of treatment-naïve patients
infected with HCV genotype 1, 5 of 12 patients who received
3 mg daclatasvir with pegylated IFN-a and ribavirin for 48 weeks
achieved extended rapid virologic response (eRVR), compared
with 10 of 12 who received 10 mg daclatasvir, 9 of 12 who
received 60 mg daclatasvir, and 1 of 12 who received placebo.
Adverse events and discontinuations as a result of adverse events
occurred with similar frequency across treatment groups [44]. In
another Phase IIa trial in genotype 1-infected patients who were
non-responders to a prior course of pegylated IFN-a and ribavi-
rin, all 10 patients who received quadruple therapy with dacla-
tasvir, asunaprevir, and pegylated IFN-a/ribavirin showed a
sustained virologic response (SVR) after 12 weeks, as opposed
to 4 of 11 who received daclatasvir and asunaprevir only [45].
A higher incidence of viral breakthrough due to resistance was
observed in genotype 1a patients who were given only the 2
DAAs without pegylated IFN-a/ribavirin vs. genotype 1b patients
receiving the same treatment regimen, as a result of the lower
barrier to resistance in genotype 1a [45]. Among patients who
experienced virologic failure, the most common variants har-
boured Y93H and L31M, two substitutions well known for confer-
ring resistance to daclatasvir.
In a 24-week dual-oral Phase II trial with daclatasvir and
asunaprevir in genotype 1b-infected patients, 90.5% of null
responders and 63.6% of patients ineligible for or intolerant to
pegylated IFN-a/ribavirin achieved SVR 24 weeks after the end
of treatment (SVR24) [46]. Interestingly, many patients in this
study with pre-existing resistance-associated NS5A polymor-
phisms were cured of their chronic HCV infection.
In a Phase IIb study with daclatasvir, pegylated IFN-a, and
ribavirin, 100% of genotype 4-infected patients achieved SVR at
12 weeks post-treatment (SVR12) [47]. A combination of dacla-
tasvir and sofosbuvir (formerly GS-7977), a nucleotide analogue
inhibitor of HCV RdRp developed by Gilead Sciences, given for
24 weeks achieved SVR in 100% (44/44) of treatment-naïve
patients infected with HCV genotype 1, and in 91% (40/44) of
patients infected with HCV genotypes 2 and 3 at 4 weeks post-
treatment. Addition of ribavirin had no effect on SVR rates [48].
Finally, the triple combination of daclatasvir, asunaprevir and
BMS-791325, a non-nucleoside inhibitor of HCV RdRp, resulted
in an SVR12 in 15 of 16 patients (94%) treated for 12 weeks (data
missing in the remaining patient) [49].
ABT-267
This drug candidate, developed by AbbVie, is in Phase II clinical
trials. It is an oral, once-daily NS5A inhibitor that signiﬁcantly
reduces HCV RNA levels in vitro and in vivo. In a study of treat-
ment-naïve genotype 1-infected patients, ABT-267 in combina-
tion with pegylated IFN-a and ribavirin produced a rapid
virologic response (RVR) at 4 weeks in 22 of 28 patients as com-
pared with 2 of 22 who received placebo; after 12 weeks, 25 of 28
patients receiving the NS5A inhibitor in combination with pegy-
lated IFN-a and ribavirin showed complete early virologic
response (cEVR) compared with 6 of 9 patients in the placebo
group. A recently presented Phase IIb clinical trial, which used
a 4-drug combination of ABT-267, ritonavir-boosted ABT-450 (a
protease inhibitor), ABT-333 (a non-nucleoside inhibitor of HCV378 Journal of Hepatology 201RdRp), and ribavirin achieved SVR12 in 97.5% of treatment-naïve
patients and in 93.3% of prior null-responders infected with geno-
type 1 [50,51]. In treatment-naïve patients, the SVR rates were
87.5% when the three drugs and ribavirin were administered
for 8 weeks, 89.9% when ABT-267 was administered with ABT-
450 and ribavirin for 12 weeks, and 87.3% when the three DAAs
were administered without ribavirin for 12 weeks. In null
responders, the SVR rate was 88.9% with the combination of
ABT-450, ABT-267, and ribavirin. Based on these results, Phase
III trials with the 3 DAAs with and without ribavirin are planned
[51].Ledispasvir (GS-5885)
This oral, once-daily drug candidate, developedbyGilead Sciences,
is a potent NS5A inhibitor against genotypes 1a, 1b, 4a, and 5a
in vitro, but has lower activity against genotypes 2a and 3a [52].
In a randomized, placebo-controlled study of 14 days of ledipasvir
monotherapy in genotype1-infectedpatients, signiﬁcantHCVRNA
reductions (up to 1000-fold) were observed. Several resistance-
associated substitutions were selected, including the aforemen-
tioned Y93H and L31M. In patients infected with HCV genotype
1b, daclatasvir has been reported to bemore active than ledipasvir,
whereas ledipasvir has been found to be 4–5 times more active
than daclatasvir for the M28T and Q30H substitutions in HCV
genotype 1a infection. In addition, daclatasvir has been demon-
strated to be 2-fold more active against the L31M substitution as
compared with ledipasvir [53]. Ledipasvir is now in a Phase II trial
as a component of a 4-drug regimen with tegobuvir (a non-nucle-
oside inhibitor of HCV RdRp), GS-9451 (an NS3/4A protease inhib-
itor), and ribavirin [52]. Recent results from the ELECTRONPhase II
trial have shown SVR rates 12 weeks after the end of treatment of
100% in 25 treatment-naïve and 10 null responder patients
infected with HCV genotype 1 with the combination of sofosbuvir,
ledipasvir and ribavirin [54]. A Phase III trial with a ﬁxed-dose
combination of sofosbuvir and ledipasvir, with or without ribavi-
rin, is in progress in treatment-naïve patients infected with HCV
genotype 1 [55]. A recent presentation also showed that ledipasvir,
in combination with GS-9451, pegylated IFN-a, and ribavirin
achieved SVR at 4 weeks post-treatment in 100% of CC IL28B
patients infected with HCV genotype 1 [56].GSK-2336805
This oral, once-daily drug candidate is being developed by Glaxo-
SmithKline. Preliminary studies show that GSK-2336805 is par-
ticularly effective against HCV genotype 1b, and has potent
antiviral activity against other genotypes as well. A placebo-con-
trolled Phase I study of treatment-naïve patients with chronic
genotype 1 infection found a reduction in HCV RNA level of up
to 1000-fold following 14 days of monotherapy. This NS5A inhib-
itor is currently in Phase II clinical trials in treatment-naïve
patients infected with HCV genotype 1 in combination with pegy-
lated IFN-a, ribavirin, and telaprevir [57]. Resistance to GSK-
2336805 maps to NS5A [58].
ACH-2928
This oral, once-daily drug candidate, developed by Achillion
Pharmaceuticals, displays highly potent activity in vitro against3 vol. 59 j 375–382
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genotype 1a replicons as well as chimeric replicons of genotypes
2–6. ACH-2928 has demonstrated in vitro synergistic activity in
combination with sovaprevir (formerly ACH-1625), an HCV
NS3/4A protease inhibitor, which is further enhanced by ribavirin
[59]. In Phase I trials, ACH-2928 monotherapy for 3 days pro-
duced up to a 3.7 log10 reduction in HCV RNA levels in patients
with chronic HCV genotype 1 infection [60].
BMS824393
This NS5A inhibitor is being developed by Bristol-Myers Squibb.
It has shown strong in vitro potency against genotypes 1a and
1b. In a Phase I study in which this agent was used as a mono-
therapy for 3 days in genotype 1-infected patients, a decline of
up to 3.9 log10 was observed [61].
IDX719
This drug candidate, developed by Idenix Pharmaceuticals, has
shown greater potency in vitro than daclatasvir against HCV
genotypes 1a, 1b, 2a, 3a, 4a, and 5a [62]. In Phase I studies,
HCV RNA levels declined by more than 3 log10 in single-dose tri-
als for all genotype 1, 2, and 3 patients after 24 hours. Similar
reductions in HCV RNA levels (over 3 log10) were observed for
genotype 1, 3, and 4 patients, and reductions of 2 log10 for geno-
type 2, in 3-day monotherapy studies [63,64]. However, evidence
indicates that the Y93H substitution confers resistance to this
NS5A inhibitor [62]. A Phase II clinical trial using IDX719, sime-
previr (a protease inhibitor developed by Janssen and Medivir),
and TMC647055, a non-nucleoside polymerase inhibitor devel-
oped by Janssen, has been announced [65].
PPI461
This oral drug candidate is under development by Presidio
Pharmaceuticals. A Phase Ib trial of monotherapy for 3 days
in patients with HCV genotype 1 infection showed a decrease≥1000
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Fig. 2. Antiviral efﬁcacy of ACH-3102 (second-generation NS5A inhibitor) compared
(parent) and mutated HCV replicons [69].of HCV RNA level of up to 3.6 log10. However, widespread
resistance emerged rapidly, mapping to amino acids 28, 30,
31, and 93 [66].
PPI668
Also under development by Presidio Pharmaceuticals, this NS5A
inhibitor has been shown to possess high efﬁcacy against HCV
genotype 1, with up to 3.7 log10 mean HCV RNA reductions, in
a Phase Ib clinical trial [67,68]. Activity was demonstrated against
variants harbouring the L31M substitution. In an added geno-
type-2/3 cohort, the ﬁrst 2 patients achieved mean 3.0 log10
RNA level reductions [68]. PPI668 will be studied in combination
with two DAAs developed by Boehringer-Ingelheim, faldaprevir,
an NS3/4A protease inhibitor, and BI207127, a non-nucleoside
inhibitor of HCV RdRp.
ACH-3102
This NS5A inhibitor, developed by Achillion Pharmaceuticals, has
a modiﬁed structure designed to have a higher pharmacologic
barrier to resistance. Pharmacokinetic studies support once-daily
oral dosing with this agent. ACH-3102 has shown potent antiviral
activity against all genotypes in preclinical studies. In replicon
studies, ACH-3102 has shown the smallest difference in potency
between genotype 1a and 1b replicons, compared with daclatas-
vir and ACH-2928 [69]. ACH-3102 is potent against mutants har-
bouring substitutions that confer resistance to ﬁrst-generation
NS5A inhibitors (Fig. 2), such as those at positions Y93 and L31
[69]. Antiviral efﬁcacy is also strong against double mutants that
are highly resistant to other NS5A inhibitors (unpublished data).
In addition, this inhibitor has shown very low potential for emer-
gence of resistant variants in genotype 1b replicons (unpublished
data). For these reasons, ACH-3102 is considered a ‘‘second-gen-
eration’’ NS5A inhibitor.
A recently reported preclinical study using ACH-3102 and
ACH-2684 (an NS3/4A protease inhibitor) has shown an additiveM2
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Key Points
• Novel drug candidates that inhibit the viral 
nonstructural protein 5A (NS5A) of HCV have been
demonstrated to possess high potency, pan-genotypic
activity, and a high barrier to resistance
• The exact mechanism of antiviral action of NS5A 
inhibitors is unknown, but available evidence suggests
that they have multiple effects on replication and viral
assembly
• First-generation NS5A inhibitors have a low barrier to
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to synergistic antiviral effect against genotypes 1a and 1b
without the emergence of resistance variants [70]. Recently
announced results from a Phase Ia trial in patients infected
with HCV genotype 1 show that a single dose of ACH-3102
produces a mean HCV RNA level reduction of up to 3.9 log10,
with an upper range of 4.6 log10, with inhibition lasting for
4 days after dosing. Moreover, ACH-3102 has a half-life of
approximately 250 hours (unpublished data), compared with
13–15 hours for daclatasvir [71], 22–50 hours for ledipasvir
[53], and 25–32 hours for ABT-267 [72]. A single Phase II trial
has been initiated in genotype 1b patients using ACH-3102 in
combination with ribavirin [73].resistance for genotype 1a, an issue partly resolved
with second-generation NS5A inhibitors
• A large number of NS5A inhibitors are currently 
assessed in clinical trials, in combination with 
pegylated IFN and ribavirin, with a nucleotide 
analogue, or with an NS3/4A protease inhibitor and a
non-nucleoside inhibitor of the HCV RNA polymeraseProgress toward all-oral combination therapies for HCV and
the role of NS5A inhibitors
Currently, the standard of care for chronic HCV genotype 1
infection is a combination of pegylated IFN-a, ribavirin, and
an NS3/4A protease inhibitor (i.e., boceprevir or telaprevir),
whereas patients infected with other HCV genotypes continue
to be treated with pegylated IFN-a and ribavirin. The SVR rates
observed with the triple combination in patients infected with
HCV genotype 1 range from 67% to 75% in clinical trials
[74,75]. They are probably lower in the real-life setting, indi-
cating that a signiﬁcant proportion of patients will still experi-
ence virologic failure and that improved therapeutic regimens
are needed. In addition, patients receiving pegylated IFN-a
and ribavirin experience a plethora of adverse effects, some
of which are aggravated by the protease inhibitor [6,7,76]. Clin-
ical trials of NS5A inhibitors in combination with pegylated
IFN-a and ribavirin have shown promising results. However,
the trials conducted thus far have included only small numbers
of patients, and more studies are needed before the efﬁcacy of
such 3-drug combinations can be fully ascertained. In this
respect, the results of a Phase III trial with daclatasvir, pegylat-
ed IFN-a, and ribavirin are awaited. Quadruple therapies
including an NS5A inhibitor, pegylated IFN-a, ribavirin, and
another DAA also appear promising. However, recent reports
of very high SVR rates, over 90%, in patients treated with all-
oral, IFN-free regimens with or without ribavirin clearly indi-
cate that the IFN era is coming to an end. It is also noteworthy
that NS5A inhibitors developed by one company have been
used with different classes of DAAs developed by other compa-
nies [48]; as such, a highly potent NS5A inhibitor may ﬁnd
uses in combinations with various other DAAs to achieve high
cure rates.
Due to their speciﬁcity, potency, and low EC50, NS5A inhib-
itors will likely be a critical component of future all-oral, IFN-
free combinations. It is interesting to note that the most attrac-
tive all-oral combinations presented at the last annual meet-
ings of the American and European liver societies all
contained an NS5A inhibitor, combined either with a nucleo-
tide analogue or a protease inhibitor and a non-nucleoside
inhibitor of HCV RdRp, with or without ribavirin. Fixed-dose
combinations (i.e., 2-drug combinations in 1 pill) including an
NS5A inhibitor are already available in Phase II and III clinical
trials. The advent of second-generation NS5A inhibitors, with a
modiﬁed structure and near-equal efﬁcacy against variants
known to resist ﬁrst-generation NS5A inhibitors, is also
promising.380 Journal of Hepatology 201Conclusions
Although blood screening and other preventive measures have
reduced the incidence of HCV in some parts of the world, infec-
tion with this virus remains a signiﬁcant worldwide health con-
cern. The multiple genotypes of HCV, as well as rapid
development of mutations, have complicated the development
of effective drugs. Until recently, a non-speciﬁc antiviral combi-
nation, pegylated IFN-a and ribavirin, was the mainstay of HCV
therapy. The approval of two NS3/4A protease inhibitors has
allowed the addition of a DAA to this treatment regimen.
Although the ﬁrst-generation protease inhibitors, telaprevir and
boceprevir, in combination with pegylated IFN-a and ribavirin,
have improved treatment of chronic HCV genotype 1 infection,
response rates remain suboptimal. In addition, many patients
are unable to tolerate this therapy and, among those who can,
adverse events associated with the drugs can compromise patient
compliance and lead to premature treatment discontinuations.
Thus, there has been a strong desire to develop all-oral, IFN-free
therapies with high efﬁcacy. The discovery of the multiple roles
of the NS5A protein in viral replication has been paralleled by
the development of speciﬁc NS5A inhibitors. Evidence gathered
thus far indicates that these agents are potent and possess anti-
viral activity against multiple HCV genotypes with acceptable
safety proﬁles. In addition, clinical trial data support the efﬁcacy
of NS5A inhibitors with and without pegylated IFN-a and ribavi-
rin, suggesting an important role for these agents as a component
of all-oral therapeutic regimens for the treatment of HCV.Financial support
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